Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 477 shares of the firm's stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $49.08, for a total transaction of $23,411.16. Following the completion of the transaction, the senior vice president owned 2,426 shares in the company, valued at approximately $119,068.08. The trade was a 16.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Jolanda Howe also recently made the following trade(s):
- On Wednesday, July 2nd, Jolanda Howe sold 564 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $48.25, for a total transaction of $27,213.00.
Mirum Pharmaceuticals Price Performance
Shares of NASDAQ:MIRM traded up $0.84 during midday trading on Friday, hitting $49.93. The stock had a trading volume of 216,684 shares, compared to its average volume of 464,541. The company's 50-day moving average price is $46.46 and its 200-day moving average price is $45.56. The company has a market capitalization of $2.47 billion, a P/E ratio of -31.01 and a beta of 0.97. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $34.47 and a fifty-two week high of $54.23. The company has a quick ratio of 3.04, a current ratio of 3.22 and a debt-to-equity ratio of 1.32.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative net margin of 20.39% and a negative return on equity of 33.63%. The business had revenue of $111.59 million for the quarter, compared to analyst estimates of $98.47 million. During the same period in the prior year, the firm earned ($0.54) earnings per share. Mirum Pharmaceuticals's revenue was up 61.2% on a year-over-year basis. As a group, equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.
Wall Street Analyst Weigh In
MIRM has been the topic of several research analyst reports. Raymond James Financial reissued a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research note on Tuesday, May 13th. JMP Securities lifted their target price on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a research report on Friday, May 9th. Wall Street Zen downgraded shares of Mirum Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Sunday. Finally, HC Wainwright reiterated a "buy" rating and issued a $73.00 target price on shares of Mirum Pharmaceuticals in a research note on Monday, May 19th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $65.50.
Check Out Our Latest Research Report on MIRM
Institutional Investors Weigh In On Mirum Pharmaceuticals
Several institutional investors have recently bought and sold shares of the stock. CWM LLC raised its position in Mirum Pharmaceuticals by 259.4% during the 1st quarter. CWM LLC now owns 593 shares of the company's stock valued at $27,000 after purchasing an additional 428 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in Mirum Pharmaceuticals by 100.0% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after purchasing an additional 357 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Mirum Pharmaceuticals during the 4th quarter valued at $35,000. Comerica Bank boosted its stake in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company's stock worth $40,000 after buying an additional 278 shares during the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in Mirum Pharmaceuticals in the 4th quarter worth $42,000.
About Mirum Pharmaceuticals
(
Get Free Report)
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Featured Articles
Before you consider Mirum Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mirum Pharmaceuticals wasn't on the list.
While Mirum Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
